Member Info for ChrisToffer

It was RNS'd, last week. The comments from RM are new and the fact he hasn't done an SNG (proactive) interview suggests to me that there's a piece of this puzzle still missing.

Yea a few on here have mentioned their brokers won't do the same so I'm not counting my chickens till its done!

Thanks Jint, reassuring to hear you got told the same thing! Hopefully have the corporate action tomorrow. Be a shame the lose the allocation as I was fully loaded on the ISA before 20th July.

Halifax told me on the phone that I can purchase my full allocation (inc. ISA where I've used my full allowance) on my normal account. They said to call them, though I haven't got the corporate action yet so still to test this.

Quickbuck, thats sounds like you may be over complicating the matter. Im in exactly the same situation with an ISA where i've used my full entitlement.

I called the Halifax the other day and they said I can call them and purchase my full entitlement (ISA included) in my normal shares account.

Morning everyone,

Is there a link available to Professor Holgates interview the other day? Couldn't make it myself.

"Somewhere in all the medical blurb will be a reason for no big fish participants."

The medical blurb is solid. Maybe they weren't willing to pay the price? Regardless, the show goes on without them.

Ah get ya now! I'm not sure we'll see any TR-1 until the shares are admitted on the 19th?

HSD, yes that means they've found buyers for the £80m worth of shares. They did RNS it, yesterday morning.

They used a £14m fundraise in march to turn a 30m mcap into +250m. Imagine what theyll do with £87m.

Agreed. I actually think this latest move by the company where they will take the drug market without JV/partnership , though it comes with more risk, moves the potential from a £2-5b mcap to £5-10b.

Exactly CityTT, like £90-£180 a share. Their assumptions don't stand up to much scrutiny.

It's a inconsistent broker note. £300m a month would £3000 a treatment which is a very high assumption. That would mean best case 3.6B in revenue which is an enormous Mcap. Way waaayyyy more than £4.20 a share.

Potential peak revenues of 300m a month! and only a £4.20 target?!?!

It's also 4 weeks from the submission of the IND application before they can start the P3 trial.

Brilliant Robort haha!

Hayashi, the difference in here and AVCT (their test dev.) is that the testing market is highly diluted. If they get a POC test to market it will be huge but nothing compared to a therapeutic that's proven to save lives!

You're a man of few words Punit!

Alubush, that's the SG016 trial. The phase 3 has the SG018 designation. In any case, end dates are only there as a marker. Completion of any trial is driven by recruitment. There may also be scope in the P3 to stop the trial early if results are overwhelming.

The running of a P3 trial does not necessarily rule out emergency authorisations in the interim.

That can't be right mortgagefreeman;

Latest time and date for receipt of Application Forms and payment in full under the Open Offer and settlement of relevant CREST instructions (as appropriate)

11.00 a.m. on 30 October 2020

Hi Surfer, not sure when the corporate action will come through but we have to 30th October anyway so not too bothered.